Intellectual Property Watch; MSF Challenges Gilead Hepatitis C Patent In China
"According to the [Médecins Sans Frontières (MSF, Doctors Without Borders) press] release, “Gilead launched the sofosbuvir/velpatasvir
combination at a price of US$51,000 for a 12-week treatment course in
the United Kingdom, whereas the same treatment course is available for
as low as $286 in India from generic manufacturers. In China, this
combination was registered in May 2018, but Gilead has not yet announced
its price.”
No comments:
Post a Comment